DCIS (ductal carcinoma in situ) is a non-invasive breast cancer.
In DCIS, the abnormal cells are contained in the milk ducts (canals that carry milk from the lobules to the nipple openings during breastfeeding). It’s called “in situ” (which means "in place") because the cells have not left the milk ducts to invade nearby breast tissue.
DCIS is also called intraductal (within the milk ducts) carcinoma. You may also hear the terms “pre-invasive” or “pre-cancerous” to describe DCIS.
DCIS is treated to try to prevent the development of invasive breast cancer.
DCIS can be found alone or with invasive breast cancer.
If DCIS is diagnosed with invasive breast cancer, treatment and prognosis are based on the invasive breast cancer (not the DCIS).
Learn about treatment for early breast cancer.
DCIS is non-invasive, but without treatment, the abnormal cells could turn into invasive cancer over time.
Left untreated, about 40-50 percent of DCIS cases may progress to invasive breast cancer . (These numbers are estimates.)
Higher grade DCIS may be more likely than lower grade DCIS to turn into invasive cancer if left untreated.
At this time, health care providers cannot predict which cases of DCIS will progress to invasive breast cancer and which will not. Because DCIS might turn into invasive breast cancer, almost all cases of DCIS are treated.
Surgery (with or without radiation therapy) is recommended to treat DCIS. After surgery and radiation therapy, some women may take hormone therapy.
Learn more about treatments for DCIS.
Learn about the risk of invasive breast cancer after treatment for DCIS.
Learn more about emerging areas in the treatment of DCIS.
Although the exact treatment for DCIS varies from person to person, guidelines help ensure high quality care. These guidelines are based on the latest research and agreement among experts.
The National Comprehensive Cancer Network (NCCN) and the American Society of Clinical Oncology (ASCO) are two respected organizations that regularly review and update their guidelines.
In addition, the National Cancer Institute (NCI) provides treatment overviews.
With treatment, prognosis for DCIS is usually excellent.
Surgery is the first step to treat DCIS. It removes the abnormal tissue from the breast.
Depending on how far the DCIS has spread within the milk ducts, surgery can be either mastectomy or lumpectomy.
If DCIS has spread throughout the ducts, affecting a large part of the breast, a total (simple) mastectomy will be done. In a total mastectomy, the surgeon removes the entire breast and possibly some lymph nodes, but no other tissue.
If there is little spread of DCIS within the ducts, a choice can be made between mastectomy or lumpectomy.
With lumpectomy, the surgeon removes only the abnormal tissue, and the rest of the breast is left intact. Lymph nodes are not usually removed.
Overall survival is the same for women with DCIS who have mastectomy and those who have lumpectomy (with or without radiation therapy) .
In the U.S., most women with DCIS choose lumpectomy followed by radiation therapy .
A sentinel node biopsy is a procedure used to check whether or not invasive breast cancer has spread to the lymph nodes in the underarm area (axillary nodes). It removes 1-5 nodes.
Once a mastectomy has been done, a person cannot have a sentinel node biopsy at a later date. So, even though a sentinel node biopsy may not be needed with DCIS, most people who have a mastectomy for DCIS will also have a sentinel node biopsy done at the same time. That way, if it turns out there is also invasive breast cancer (in addition to DCIS) in the tissue removed during the mastectomy, the sentinel node biopsy will have already been done.
This helps some people with DCIS avoid an axillary dissection, which removes more axillary lymph nodes than a sentinel node biopsy.
Radiation therapy isn't given to women who are treated with mastectomy for DCIS.
Lumpectomy for DCIS is usually followed by radiation therapy to lower the risk of [2-8]:
Some women with smaller, lower grade DCIS and clean surgical margins, may be able to have lumpectomy without radiation therapy [2,9].
Overall survival is the same for women with DCIS who have lumpectomy with or without radiation therapy [2,4].
For a summary of research studies on lumpectomy plus radiation therapy in the treatment of DCIS, visit the Breast Cancer Research Studies section.
A pathologist determines the hormone receptor status by testing the tissue removed during a biopsy.
Hormone receptor-positive DCIS may benefit from hormone therapy (tamoxifen or an aromatase inhibitor) [2,6,12].
Learn about hormone receptor status and invasive breast cancer.
Hormone therapy isn’t recommended for women who have a mastectomy for DCIS.
These women have an excellent prognosis with a very low risk of DCIS recurrence or developing breast cancer in the opposite breast. So, the benefit of hormone therapy is likely very small and would mostly affect the risk of cancer in the opposite breast.
The National Comprehensive Cancer Network (NCCN) recommends women who are treated with lumpectomy for estrogen receptor-positive DCIS consider taking hormone therapy (tamoxifen or an aromatase inhibitor) for 5 years .
In women treated with lumpectomy and radiation therapy for DCIS, studies have shown hormone therapy can lower the risk of [10-14]:
Learn more about factors that affect treatment options.
For a summary of research studies on tamoxifen as a treatment for DCIS, visit the Breast Cancer Research Studies section.
After treatment for DCIS there is still a small risk of:
These risks are higher with lumpectomy plus radiation therapy than with mastectomy .
However, overall survival is the same after either treatment .
With close follow-up, invasive breast cancer is usually caught early and can be treated successfully.
Learn more about talking with your health care provider.
In 2013, the Health and Medicine Division of the National Academy of Sciences (formerly the Institutes of Medicine) released a set of recommendations (below) on improving cancer care in the U.S. The report, Delivering High-Quality Cancer Care: Charting a New Course for a System in Crisis recommended improvements to fix shortcomings that add cost and burden to cancer care. Susan G. Komen® was one of 13 organizations that sponsored this study.
The report identified key ways to improve quality of care:
Read the full report.
*Please note, the information provided within Komen Perspectives articles is only current as of the date of posting. Therefore, some information may be out of date at this time.
Breast Cancer 101 - Treatment for Stage 0
Ductal Carcinoma in Situ
1-877 GO KOMEN(1-877-465-6636)
What gives you strength during treatment?